Healthcare / BiotechnologyTaipei Exchange
$138.00
+2.00 (+1.47%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 22% · confianza 25%
FCF escenarios
weak_data · normalized FCF $434.8M · quality 87.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
52/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$14.0B
P/E
29.7x
↑EV/EBITDA
21.7x
↑ROE
28.1%
↑Gross Margin
70.9%
↑Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+17.5%
FCF CAGR
+19.2%
FCF margin
52.1%
FCF / Net income
1.24x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.02B · net income $429.4M · FCF $530.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.02B | $1.02B | $933.8M | $758.4M | $627.5M |
| Net Income | $429.4M | $429.4M | $367.3M | $539.4M | $200.7M |
| EBITDA | $548.4M | $548.4M | $491.8M | $655.5M | $300.2M |
| EPS | — | — | 4.14 | 5.97 | 2.20 |
| Gross Margin | 70.9% | 70.9% | 70.7% | 63.9% | 66.1% |
| Operating Margin | 43.1% | 43.1% | 49.9% | 44.5% | 45.2% |
| Net Margin | 42.2% | 42.2% | 39.3% | 71.1% | 32.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.00 | 0.00 | 0.01 |
| Current Ratio | 1.76 | 1.76 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $530.6M | $530.6M | $434.8M | $415.9M | $313.6M |
| Returns | |||||
| ROE | 28.1% | 28.1% | 20.5% | 29.3% | 11.2% |
| Valuation | |||||
| P/E | 29.68 | 29.68 | 36.91 | 26.16 | 70.33 |
| EV/EBITDA | 21.71 | 21.71 | 26.98 | 21.01 | 45.86 |
| P/B | 7.92 | 7.92 | 7.56 | 7.65 | 7.87 |
| Growth & Yield | |||||
| Revenue Growth | 9.0% | 9.0% | 23.1% | 20.9% | — |
| EPS Growth | — | — | -30.7% | 171.7% | — |
| Dividend Yield | 2.5% | 2.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-4.3%
Start / end P/E
n/dx → n/dx
EPS bridge
4.14 → n/d
Residual
-6.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.